Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 53, 2019 - Issue 1
Journal homepage
467
Views
13
CrossRef citations to date
0
Altmetric
Articles

Osteoporosis and prostate cancer; a 24-month prospective observational study during androgen deprivation therapy

Mads Hvid PoulsenDepartment of Urology, Odense University Hospital, Odense, Denmark; ;Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark; Correspondence[email protected]
,
Morten FrostDepartment of Endocrinology, Odense University Hospital, Odense, Denmark; ;Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark;
,
Bo AbrahamsenDepartment of Medicine and Endocrinology, Holbaek Hospital, Holbaek, Denmark; ;OPEN, Department of Clinical Research, University of Southern Denmark, Odense, Denmark;
,
Oke GerkeDepartment of Nuclear Medicine, Odense University Hospital, Odense, Denmark;
,
Steen WalterDepartment of Urology, Odense University Hospital, Odense, Denmark; ;Department of Clinical Research, University of Southern Denmark, Odense, Denmark
&
Lars LundDepartment of Urology, Odense University Hospital, Odense, Denmark; ;Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark; ;Department of Clinical Research, University of Southern Denmark, Odense, Denmark
Pages 34-39 | Received 25 Jul 2018, Accepted 11 Jan 2019, Published online: 19 Feb 2019

References

  • Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg Gynecology Obstet. 1967;124:1011–1017.
  • Glass TR, Tangen CM, Crawford ED, et al. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003;169:164–169.
  • Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036–1042.
  • Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–642.
  • Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300.
  • Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: A review. JAMA. 2017;317:2532–2542.
  • Frydenberg M, Woo HH. Early androgen deprivation therapy improves survival, but how do we determine in whom? Eur Urol. 2018;73:519–520.
  • Shahinian VB, Kuo YF, Freeman JL, et al. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615–1624.
  • Schroder F, Crawford ED, Axcrona K, et al. Androgen deprivation therapy: past, present and future. BJU Int. 2012;109: 1–12.
  • Poulsen MH, Frost M, Abrahamsen B, et al. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy. Scand J Urol. 2014;48:350–355.
  • Isbarn H, Boccon-Gibod L, Carroll PR, et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol. 2009;55:62–75.
  • Sun M, Choueiri TK, Hamnvik OP, et al. Comparison of gonadotropin-releasing hormone agonists and orchiectomy: Effects of androgen-deprivation therapy. JAMA Oncol. 2016;2:500–507.
  • Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367:2010–2018.
  • Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab. 2010;95:3–10.
  • Rachner TD, Coleman R, Hadji P, et al. Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol. 2018;6:901–910.
  • Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301:513–521.
  • Beebe-Dimmer JL, Freedland SJ. Androgen deprivation therapy: further confirmation of known harms. BJU Int. 2013;111:690–691.
  • Abrahamsen B, Nielsen MF, Eskildsen P, et al. Fracture risk in Danish men with prostate cancer: A nationwide register study. BJU Int. 2007;100:749–754.
  • Kaipia A, Riikonen J, Norja H, et al. Androgen ablation for low-risk prostate cancer is common among male hip fracture patients. Scand J Urol. 2014;48:189–194.
  • Miyaji Y, Saika T, Yamamoto Y, et al. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology. 2004;64:128–131.
  • Morote J, Orsola A, Abascal JM, et al. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol. 2006;175:1679–1683.
  • Ryan CW, Huo D, Demers LM, et al. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006;176:972–978.
  • Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745–755.
  • Hoiberg M, Nielsen TL, Wraae K, et al. Population-based reference values for bone mineral density in young men. Osteoporos Int. 2007;18:1507–1514.
  • Kanis JA, Johansson H, Harvey NC, et al. A brief history of FRAX. Arch Osteoporos. 2018;13:118
  • Denham JW, Joseph D, Lamb DS, et al. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol. 2014;15:1076–1089.
  • Kirk PS, Borza T, Shahinian VB, et al. The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer. BJU Int. 2018;121:558–564.
  • Harmouch SS, Berger AJ, Cole AP. Low rates of bone density testing in prostate cancer survivors on androgen-deprivation therapy: where do we go from here? BJU Int. 2018;121:492–493.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.